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Abstract 
Annexin A1 (ANXA1) is an endogenously produced anti-inflammatory protein, which 
plays an important role in the pathophysiology of diseases associated with chronic 
inflammation. We demonstrate that patients with type-2 diabetes have increased plasma 
levels of ANXA1 when compared to normoglycemic subjects. Plasma ANXA1 
positively correlated with fatty liver index and elevated plasma cholesterol in patients 
with type-2 diabetes, suggesting a link between aberrant lipid handling and ANXA1. 
Using a murine model of high fat diet (HFD)-induced insulin resistance, we then 
investigated (a) the role of endogenous ANXA1 in the pathophysiology of HFD-
induced insulin resistance using ANXA1-/- mice, and (b) the potential use of hrANXA1 
as a new therapeutic approach for experimental diabetes and its microvascular 
complications. We demonstrate that: (1) ANXA1-/- mice fed a HFD have a more severe 
diabetic phenotype (e.g. more severe dyslipidemia, insulin resistance, hepatosteatosis 
and proteinuria) compared to WT mice fed a HFD; (2) treatment of WT-mice fed a 
HFD with hrANXA1 attenuated the development of insulin resistance, hepatosteatosis 
and proteinuria. We demonstrate here for the first time that ANXA1-/- mice have 
constitutively activated RhoA.  Interestingly, diabetic mice, which have reduced tissue 
expression of ANXA1, also have activated RhoA. Treatment of HFD-mice with 
hrANXA1 restored tissue levels of ANXA1 and inhibited RhoA activity, which, in turn, 
resulted in restoration of the activities of Akt, GSK-3β and eNOS secondary to re-
sensitization of IRS-1 signaling. We further demonstrate in human hepatocytes that 
ANXA1 protects against excessive mitochondrial proton leak by activating FPR2 under 
hyperglycaemic conditions. In summary, our data suggest that a) ANXA1 is a key 
regulator of RhoA activity, which restores IRS-1 signal transduction and b) 
recombinant human ANXA1 may represent a novel candidate for the treatment of T2D 
and/or its complications. 
 
Keywords: Type-2 diabetes, metabolism, Annexin A1, nephropathy, 
hepatosteatosis, Rho A, 
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Introduction  
Obesity and metabolic syndrome are of global health concern and are an independent 
risk factor of diseases characterized by systemic inflammation such as type-2 diabetes 
mellitus (T2D), non-alcoholic fatty liver disease (NAFLD/NASH)(1), chronic kidney 
disease (CKD) (2) and cardiovascular disease (3).  Even with aggressive strategies to 
modulate both plasma lipid profiles and blood glucose levels, microvascular 
complications develop over time in patients with T2D (4). Indeed, approximately 30% 
of patients with T2D develop diabetic nephropathy, which is the leading cause of end-
stage renal disease (ESRD). Peripheral insulin resistance drives a vicious 
pathophysiological cycle leading to T2D, ectopic adiposity and chronic inflammation, 
coupled with a down-regulation of pro-survival/anti-inflammatory pathways. 
Identifying endogenous molecules that are both anti-inflammatory and tissue protective 
agents will lead to the discovery of novel drug target for the treatment of diabetes. 
Annexin A1 (ANXA1) is an endogenous anti-inflammatory protein, principally known 
as a regulator of peripheral leukocyte migration and a promoter of macrophage 
phagocytosis of apoptotic neutrophils (5).  ANXA1 is expressed by endothelial cells, 
tubular epithelial cells, adipocytes and low levels of ANXA1 can be detected in the 
circulation under physiological conditions. We recently demonstrated that the plasma 
levels of ANXA1 are elevated in patients with type-1 diabetes (6) and multiple sclerosis 
(7). Cristante et al. (7) demonstrated a mechanistic link between RhoA and ANXA1, 
whereby ANXA1 interacts with RhoA to alter actin-polymerization and maintain blood 
brain barrier integrity. RhoA has far reaching implications in many diseases including 
type-2 diabetes, its activity is upregulated by oxidative stress and hyperglycemia. Many 
strategies, which inhibit the Rac/RhoA pathway, also reduce microvascular 
complications in diabetes via a reduction in inflammation and fibrosis (8)(9). 
 
In the present study, we use a translational approach to gain a better insight into the role 
of ANXA1 in a) patients with T2D and b) a murine model of high fat diet (HFD) 
induced insulin resistance. Moreover, we investigated the effect of human recombinant 
ANXA1 (hrANXA1) as a potential treatment for experimental T2D and its 
microvascular complications.  
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Methods 
Human studies and subjects and ethic statement 
Human volunteers and patients were recruited within the general population enrolled 
in the PLIC study (Progressione delle Lesioni Intimali Carotidee) at the Center for the 
Study of Atherosclerosis, SISA Bassini Hospital Cinisello B. Italy (Ethical approval 
SEFAP/Pr0003F University of Milan 06/2/2001) (10). Patients with T2D were 
identified from their clinical history, outpatient’s registries and/oral hospital archives, 
following international guidelines (11). Subjects included in the study were defined as 
“normoglycemic” if the following criteria were met: No self-reported T2D, patients are 
not being treated with glucose lowering drugs and fasting glucose levels are below 110 
mg/dL (at least 3 previous controls). All patients and healthy volunteers gave written 
informed consent in adherence to the Declaration of Helsinki. Clinical data was 
collected, and biochemical analyses were performed as previously described (12). 
Urinary albumin levels were determined by immunoturbidimetry on fresh samples of 
the morning. Fatty Liver Index was calculated from BMI, waist circumference, gamma-
glutamyl-transpeptidase (GGT) and triglyceride levels in fasting condition as 
previously described (13). 
 
Healthy subjects” from the PLIC cohort were only included if they had no evidence of 
hepatic steatosis (ultrasound determined, not shown), renal damage or type-2 diabetes 
(T2D). Clinical information [clinical and pharmacological history, Body Mass Index 
(BMI) and waist-hip ratio (waist)] was collected during the outpatient activity, which 
was part of the study design of PLIC. Biochemical, lipid profile (LDL-C “LDL 
cholesterol levels”), liver enzymes (including gamma-glutamyl-transferase), C-reactive 
protein (CRP) and glucose level were determined as previously described (12). Briefly, 
blood samples were drawn after overnight fasting (ten hours at least) from antecubital 
vein and collected in EDTA tubes (BD Vacuette). Blood samples were then 
centrifuged at 3’000 rpm for 12 minutes in order to separate plasma for glucose 
quantification. Determination was performed by enzymatic method (hexokinase 
reaction) through automatic sample analyzer (RX Daytona, Randox Laboratories Ltd, 
Crumlin, UK). 
Fatty liver Index (FLI) was determined as previously described, according to the 
following formula: FLI= (e0.953*loge(triglycerides) + 0.139*BMI + 0.718*loge(GGT) + 0.053*waist 
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circumference – 15.745) / (1 + e0.953*loge(triglycerides) + 0.139*BMI + 0.718*loge(GGT) + 0.053*waist circumference – 
15.745) * 100.  
Chronic kidney disease (CKD) and its stages (CKD3, CKD4, and CKD5) were 
determined following determination of glomerular filtration rate (GFR), according to 
validated international criteria. When compared to healthy controls, CKD patients had 
a GFR of less than 60 ml/min/1.73 m2 associated with albuminuria (urinary albumin 
over 30 mg/g of total urinary proteins).  
 
Use of experimental animals-ethics statement 
The experimental protocols used in this study have been approved by the Animal 
Welfare Ethics Review Board (AWERB) of Queen Mary University of London and the 
University of Turin, the study was performed under license issued by the home office 
(Procedure Project License; PPL: 70/8052) and committees (DGSAF 0021573-P-
12/11/2013 and DGSAF). Animal care was in accordance with the Home Office 
guidance on Operation of Animals (Scientific Procedures Act 1986) published by Her 
Majesty’s Stationery Office and the Guide for the Care and Use of Laboratory Animals 
of the National Research Council and are in keeping with the European Directive 
(2010/63/EU) as well as the Guide for the Care and Use of Laboratory Animals. 
 
Animals and experimental procedures 
This study was carried out on 10 weeks old ANXA1-/- mice on a C57BL/6 background 
(14) and wild-type (WT) C57BL/6 mice, housed in the same unit under conventional 
housing conditions at 25±2 °C. WT and ANXA1-/- mice were randomly assigned either 
normal diet (chow) or high fat, high sugar diet (HFD) (D12331diet, Research Diet Inc., 
USA).  All mice had access to food and water ad libitum. After 4 weeks of dietary 
manipulation, mice were randomly assigned to a treatment group receiving either with 
hrANXA1 (40µg/kg, i.p.) or vehicle (Hepes 50mM, NaCl 140 mM i.p.) 5 days per week 
for 6 weeks. Mice were harvested the morning after receiving the last dose of hrANXA1 
(day 5 of week 6 of treatment). hrANXA1 was produced and purified as previously 
published, approximately 0.5% of injected dose per gram (ID/g) ANXA1 remained in 
the circulation 24 hours post injection as previously reported (15). 
 
ELISA for ANXA1 
 6 
A homemade sandwich ELISA was used to measure plasma ANXA1 (16). Briefly, 
ELISA-treated plates (Nunc MaxiSorp, ThermoScientific, UK) were incubated 
overnight with capture antibody 20µg/ml (mouse monoclonal antibody, generated in 
house) in bicarbonate buffer (25 mM NaHCO3, 25 mM Na2CO3, pH 9.6). The plate 
was then washed 3 times with bicarbonate buffer and blocked in blocking buffer (0.1 
% BSA, PBS) for 1 h at 37 °C.  Then 100 µl of sample and standard in assay diluent 
(Tween-20 0.05 % (v/v), PBS) were loaded and incubated for 1 h at 37 °C, then washed 
5 times with wash buffer (0.9% (w/v) NaCl, 0.05 % (v/v) Tween-20, dH2O). Following 
this wells were incubated with 1µg/ml of detecting antibody (rabbit polyclonal anti-
ANXA1; Invitrogen, UK) for 1 h at 37 °C.  After 5 washes, immuno-complexes were 
detected by adding the goat-anti-rabbit IgG with conjugated alkaline phosphatase for 
30 min.  After 5 washes, the substrate, p-nitrophenyl phosphate (Sigma Aldrich, UK) 
was added and left for 30 min for full development of color. The plate was then read 
absorbance at 405 nm and corrected at 540 nm as a reference wavelength, using a 
spectofluorometer (Tecan Infinite M200 Pro, Tecan, Austria).  
Oral glucose tolerance test (OGTT) 
Mice were fasted for 6 h prior to testing, then given an oral bolus of glucose (2g/kg in 
H2O p.o.). Blood glucose was measured from the tail vein at time 0 and then at 15 min 
intervals for 120 min using glucometer (Accu-Chek Compact System, Roche 
Diagnostics); basal non fasted blood glucose 
 
Blood and biochemical analysis 
Serum triglyceride and total cholesterol were measured by standard enzymatic assay 
using reagent kits (Hospitex Diagnostics, Italy). Liver triglycerides were measured via 
a colorimetric assay (Abnova Corporation, Germany). ALT and urine and serum 
creatinine were measured by a commercial veterinary testing laboratory (IDEXX, 
Wetherby, UK); serum insulin and urine albumin were measured using commercially 
available ELISA kits (Abcam, Cambridge, UK, and Bethyl Laboratories, 
Montgomery, TX, USA).  
 
Histological analysis 
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Oil Red – O: Frozen liver samples were embedded in OCT, and cut in 10 µm sections. 
Section were brought to room temperature, fixed with 10 % buffer formalin for 5 min, 
washed with 60 % isopropanol, then saturated with Oil Red O (1% w/v, 60 % 
isopropanol) for 15 min, washed in 60 % isopropanol and rinsed in distilled water. The 
sections were then mounted in aqueous mounting medium with coverslips. Images were 
acquired using a NanoZoomer Digital Pathology Scanner (Hamamatsu Photonics K.K., 
Japan) and analyzed using the NDP Viewer software. Additionally 10 randomly 
selected fields of view from each liver section were used to assess lipid accumulation. 
 
Periodic Acid Schiff’s: Kidney samples were obtained at the end of the experiment and 
fixed in 10 % neutral-buffered formalin for 48 h and histology staining was performed. 
Briefly, kidney tissue was embedding in paraffin and processed to obtain 4 μm sections. 
After deparaffinization and sections were rehydrated through graded alcohol to distilled 
water. The sections were then incubated with saturated in Periodic Acid Schiffs (Sigma, 
UK) solution for 30 min and washed in distilled water. Then sections were then 
dehydrated through graded alcohols and cleared before mounting with coverslips. 
Images were acquired using a NanoZoomer Digital Pathology Scanner (Hamamatsu 
Photonics K.K., Japan) and analyzed using the NDP Viewer software. Additionally 10 
randomly selected fields of view from each kidney section were used to assess 
structural alteration of the proximal convoluted tubules and general renal 
histopathology.  
 
Western Blot analysis 
Semi-quantitative western blot analyses of phosphorylated and/or total form of IRS-1, 
Akt, GSK-3β, eNOS, ANXA1, RhoA and MYPT1 were carried out in tissue samples 
as described before (6). Briefly, liver, skeletal muscle and kidney samples were 
homogenized in protein homogenization buffer and centrifuged at 1300g for 5 min at 
4°C.  To obtain the cytosolic protein fraction, supernatants were centrifuged at 16000g 
at 4°C for 40 min. Protein content was determined on cytosolic extracts using 
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Rockford, IL). 
Proteins were separated by 8% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a polyvinyldenediflouoride (PVDF) 
membrane, which were blocked with a solution of 5% dry milk in TBS-Tween for 2h. 
Membranes were incubated with a primary antibody (1:1000 rabbit anti-total IRS-1; 
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1:1000 rabbit anti-pSer307 IRS-1; 1:1000 rabbit anti-total Akt; 1:1000 rabbit anti 
pSer473 Akt; 1:1000 rabbit anti-total GSK -3β 1:1000 rabbit anti-pSer9GSK -3β; 1:200 
rabbit anti-ANXA1; 1:1000 rabbit anti-total RhoA; 1:1000 rabbit anti-pSer188 RhoA; 
1:1000 rabbit anti-total MYPT1 and 1:1000 rabbit anti-pSer853 MYPT1). Membranes 
were incubated with a secondary antibody conjugated with horseradish peroxidase 
(1:2000) for 30 min at room temperature and developed with ECL detection system. 
The immunoreactive bands were visualized by autoradiography and the densitometry 
analysis was performed using Gel Pro Analyser 4.5, 2000 software (Media Cybernetics, 
Silver Spring, MD, USA). The membranes were stripped and incubated with alpha 
tubulin monoclonal antibody (1:5000) and subsequently with an anti-mouse antibody 
(1:2000) to assess gel-loading homogeneity. Densitometry analysis of the related bands 
is expressed as relative optical density, and normalized using the related WT + vehicle 
or sham band. 
 
Oxygen consumption rate  
HepG2 cells (3x105) were seeded in 96-well Seahorse plates in serum free medium 
constaining 5.5 mM glucose, 25 mM glucose, 25 mM glucose + hrANXA1 (20µg/mL) 
or 25 mM glucose + hrANXA1 (20µg/mL) + WRW4 an FPR2 antagonist [0.9 mM-
Tocris- inhibits WKYMVm binding to FPR2 (IC50 = 0.23 μM)] and incubated for 48 h. 
to measure OCR, the medium was replaced with XF Mitoassay medium (pH 7.4) and 
incubated without CO2 for 30 min. Then, basal OCR was measured and wells were 
sequentially injected with: 1) oligomycin (1.0 μM), an ATP synthase blocker; 2) 
carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazone (FCCP) (0.5 μM), a proton 
ionophore; and 3) a mix of rotenone (0.5 μM) and antimycin A (0.5 μM), inhibitors of 
electron transport. OCR was measured three times following each injection with an 
interval of 6 minutes between each reading. Experiments were performed three times 
in triplicate and all values of OCR were normalized to protein content of individual 
wells. Data was gathered on SeaHorse XFe96 Analyzer (Agilent Technologies) and 
data analyzed using Wave Software (Agilent Technologies). 
 
Image Stream  
HepG2 cells were seeded into 6-well plates at a density of 1x106 and then treated with 
DMEM containing glucose (5.5 mM or 25 mM). After 48 h, cells were harvested and 
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fixed in paraformaldehyde (2 %) for 10 min at room temperature and washed in PBS. 
Cells were then blocked in blocking solution (PBS + 0.2 % BSA) for 30 min at room 
temperature.  To perform the staining of FPR2 on the membrane, cells were then 
incubated with primary anti-body [rabbit anti-FPR2 (1:50)] (Acris Antibodies) (30 min 
at room temperature), followed by incubation with secondary anti-body [anti-rabbit 
AF488 (1:100)] (30 min at room temperature). From intracellular FPR2 and ANXA1 
cells were permeabilized with permeabilization solution (PBS + Tween20 0.5 % v/v, 
10 min at room temperature); cells were then washed and blocked in blocking solution 
(PBS + 0.2 % BSA, 30 min at room temperature). Cells were then incubated with 
primary anti-body [rabbit anti-FPR2 (1:50)] (Acris Antibodies) and mouse anti-
ANXA1 (Invitrogen (1:100)) washed and incubated with secondary anti-body (anti-
rabbit AF647 (1:100) and anti-mouse AF405 (1:100)) (30 min at room temperature), 
and then washed. Imaging flow cytometry was performed on an ImageStreamx Mark 
II operated by INSPIRE software (Amnis Corporation). A sample of HEPG2 that were 
not incubated with antibodies were collected at the same settings, in order to gate 
different cell populations (negative or positive staining). In each experiment, a template 
of settings was created and it was applied to all files. A total of 10,000 events were 
collected for each sample, and data were analyzed using IDEAS Application 6.1 
software (Amnis Corporation). 
 
Human Phospho-kinase Array   
HepG2 cells were incubated in DMEM containing 5.5 mM glucose, 25 mM glucose, 
25 mM glucose + hrANXA1 (20µg/mL) or 25 mM glucose + hrANXA1 (20µg/mL)+ 
WRW4 (0.9 mM) and incubated for 48 h. Cells were washed in PBS containing 
protease inhibitors and cell lysates extracted as per manufactures instructions. Protein 
concentration was quantified and 600 µg of protein was used per membrane of a 
Proteome Profiler, Human Phospho-kinase Array (R&D Systems). After visualization 
of the spots, the signals were measured using Image Studio LICOR, normalization was 
carried as per manufacturers instruction and changes plotted in a heat map expressed as 
fold change to 5.5 mM glucose for each individual phosphorylation site using PRISM. 
 
Statistical analysis 
All data in the text and figures are presented as mean ± standard error mean (SEM) of 
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n observations, were n represents the number patients per group (Figure 1/2), animals 
studied (Figures 3-7) or technical replicates (Figure 8). All statistical analysis was 
calculated using GraphPad Prism 7 for Mac (GraphPad Software, San Diego, 
California, USA). Data without repeated measurements was assessed by a one-way 
ANOVA followed by Bonferroni correction. Some of the human data were analyzed 
by Student’s t-test (data with normal distribution) or Mann Whitney U test (data that 
were not normally distributed). Correlation studies were analyzed by linear regression 
using Fishers F test. In all cases a p<0.05 was deemed significant. 
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Results 
 
1. Patients with type-2 diabetes have elevated plasma levels of ANXA1 correlated 
with increased dyslipidemia and fatty liver index. 
To gain a better understanding of the role of ANXA1 in man, we compared the plasma 
levels of ANXA1 in gender- and age-matched subjects with normoglycemia or T2D 
(Table 1). Of note, patients with T2D had significantly higher circulating plasma levels 
of ANXA1 (Figure 1A) when compared with normoglycemic subjects. Moreover, the 
plasma levels of ANXA1 in patients with T2D correlated positively with fatty liver 
index, a surrogate marker of hepatic lipid accumulation (Figure 1B), and serum LDL-
C and total cholesterol (Figure 1C and D), thus implying a relation between elevated 
circulating ANXA1 levels and a complex metabolic pattern, including altered glucose 
control, hepatic steatosis and dyslipidemia.  As expected, C-reactive protein (CRP) (a 
marker of chronic low-grade inflammation) correlated positively with increased BMI 
in our cohort of patients with T2D (Figure 2A). Interestingly circulating plasma 
ANXA1 did not correlate with either BMI or CRP (Figure 2B and C). Additionally, we 
observed no correlation of CRP and lipid levels (Figure 2D and E). Additionally, 
ANXA1 levels were not further elevated in patients who presented with diabetes and 
CKD (Figure 2F). This result is particularly interesting, as a heightened level of 
systemic inflammation is classically seen in patients with CKD. Taken collectively, 
these observations suggest that the observed increase in plasma ANXA1 is not a 
consequence of increased systemic inflammation, but secondary to the altered 
metabolic state and aberrant lipid handling. 
 
2. ANXA1 attenuates the development of obesity and insulin resistance in HFD fed 
mice. 
To gain a better understanding of the role of ANXA1 in the pathophysiology of T2D, 
we used a murine model of HFD-induced insulin resistance, hepatic steatosis and renal 
dysfunction (diabetic nephropathy).  Consistent with the observation in patients with 
T2D, mice fed a HFD had elevated levels of circulating ANXA1 (Figure 3A). We also 
show that the ANXA1 protein levels were dramatically reduced in key target tissues 
(liver, kidney and skeletal muscle) of animals fed a HFD (Figure 3B) compared to chow 
fed mice.   
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When compared to chow-fed mice, WT-mice fed a HFD gained more weight (Table 2), 
had elevated levels of serum insulin, higher (non-fasted) blood glucose levels and a 
significant impairment in tolerance to oral glucose challenge (oral glucose tolerance 
test, OGTT) (Figure 2C-G). ANXA1-/- fed a HFD gained significantly more weight 
(Table 2), had higher blood glucose levels (Figure 3D) and an even more severely 
impaired OGTT (Figure 3F/G) when compared to HFD-fed WT-mice.  HFD-fed WT-
mice treated with hrANXA1 had normal tissue levels of ANXA1 (Figure 3B), lower 
serum insulin levels, lower (non-fasted) blood glucose levels (Figure 3C/D) and an 
improved OGTT (Figure 3E/G) when compared to HFD-fed WT-mice. Administration 
hrANXA1 to ANXA1-/- mice (rescue experiment) resulted in significantly lower  serum 
insulin levels, blood glucose levels, a reduction in weight gain and an improvement in 
OGTT; suggesting that endogenous ANXA1 is a key mediator of glucose homeostasis. 
 
3. ANXA1 improves IRS-1 signal transduction in HFD-induced insulin resistance. 
As endogenous ANXA1 protected against the development experimental diabetes and 
treatment with hrAXNXA1 improved the diabetic phenotype of HFD-fed mice, we next 
investigated the potential mechanisms underlying the observed beneficial effects of 
both hrANXA1 and endogenous ANXA1.  
 
When compared to WT-mice fed a chow diet, WT-mice fed a HFD exhibited an 
increase in the degree of phosphorylation of insulin substrate receptor-1 (IRS-1) on 
Ser307 in skeletal muscle (Figure 4A) and liver (Figure 4D); as well as a decrease in the 
phosphorylation of downstream effectors of the insulin signaling pathway, protein 
kinase B (Akt) on Ser473 (Figure 3B/E) and glycogen synthase kinase-3β (GSK-3β) on 
Ser9 in both skeletal muscle and liver (Figure 4C/F). All of the above findings suggest 
that WT-mice fed a HFD had developed peripheral insulin resistance.  ANXA1-/- mice 
fed a HFD exhibited a further significant increase in the degree of phosphorylation of 
IRS-1 on Ser307 in both skeletal muscle and liver (Figure 4A/D); resulting in a decrease 
in the phosphorylation of Akt on Ser473 (Figure 4B/E) and glycogen synthase kinase-
3β (GSK-3β) on Ser9 (Figure 4C/F). These data are consistent with the more severe 
diabetic phenotype observed in ANXA1-/- mice fed a HFD. 
 
Treatment of WT-mice fed a HFD with hrANXA1 attenuated the increase in 
phosphorylation of IRS-1 on Ser307, and the subsequent decrease in phosphorylation of 
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Akt on Ser473 and GSK-3β on Ser9 in both skeletal muscle (Figure 4A-C) and liver 
(Figure 4D-F). Additionally, when hrANXA1 was given to ANXA1-/- mice (rescue 
experiment), all abnormal signaling events were restored to that of WT mice fed a chow 
diet and highlighting of ANXA1 as a signaling molecule in the IRS-1 signal 
transduction pathway. 
 
4. ANXA1 attenuates dyslipidemia, steatosis, liver injury and renal dysfunction in 
HFD fed mice. 
In addition to developing insulin resistance, WT-mice fed a HFD had increased levels 
of serum triglycerides, cholesterol, a 10-fold increase in liver triglyceride levels (Figure 
5A-C) associated with an increase in Oil Red-O staining in the liver (Figure 5G), 
suggesting the development of dyslipidemia and liver steatosis. Lipid deposition and 
steatosis in the liver is associated with liver injury; WT-mice fed a HFD had elevated 
serum ALT levels (Figure 5D) compared to WT mice fed a chow diet. ANXA1-/- mice 
fed a HFD had even significantly higher serum triglyceride levels, further increased Oil 
Red-O staining in the liver and even higher ALT levels when compared to WT mice 
fed a HFD (Figure 5A-D, G). In contrast, WT-mice fed a HFD and treated with 
hrANXA1 had significantly lower serum cholesterol and liver triglyceride levels, less 
Oil Red-O staining in the liver and significantly lower ALT levels (Figure 5A-D, G) 
compared to HFD-fed WT-mice. Treatment of ANXA1-/- mice with hrANXA1 (rescue 
experiment) resulted in a reduction in liver triglyceride levels, serum ALT and Oil Red-
O accumulation in the liver compared to ANXA1-/- mice fed a HFD (Figure 5A-D, G).  
Taken together, these findings suggest that ANXA1 protects against the development 
of dyslipidemia and liver steatosis/injury. 
 
T2D ultimately drives the development of microvascular complications including 
diabetic nephropathy.  WT-mice fed a HFD exhibited an elevated albumin-to-creatinine 
ratio (ACR) and decreased creatinine clearance (Figure 5E/F) compared to chow-fed 
WT-mice, suggesting the development of proteinuria (a marker of diabetic 
nephropathy) and renal dysfunction. The development of proteinuria was associated 
with significant morphological changes. WT-mice fed a HFD have more vacuolar 
degeneration at the level of the S1-S2 segment of the proximal convoluted tubules, 
while other tubular structures of the nephron remained histologically preserved (Figure 
5H). There was also a marked loss of brush boarders in the S1-S2 segment of the 
 14 
proximal convoluted tubules (yellow arrows). All histological markers of tubular 
degeneration were more marked in the kidneys from ANXA1-/- mice fed on a HFD 
(Figure 4H). Which correlated with ANXA1-/- mice fed a HFD having further elevation 
in ACR, (Figure 5E) suggesting the development of more severe proteinuria. In 
contrast, administration of hrANXA1 to HFD-fed WT-mice attenuated the rise in ACR 
and the decrease creatinine clearance (Figure 5E/F) and preserved the kidney from signs 
of tubular degeneration (Figure 5H).   
 
5. ANXA1 regulates eNOS and RhoA activation in a model of HFD-induced 
insulin resistance 
One of the key drivers of proteinuria and, indeed, renal dysfunction is renal 
hypertension, which is, in part driven by the development of endothelial dysfunction. 
WT-mice fed a HFD had a significant reduction in the phosphorylation of eNOS on 
Ser1177 in the kidney (Figure 6) compared to chow-fed WT animals; while hrANXA1 
treatment significantly prevented the reduction in phosphorylation of eNOS on Ser1177 
(Figure 6). Moreover, ANXA1-/- mice fed a HFD also demonstrated significantly 
reduced phosphorylation of eNOS on Ser1177. Interestingly, ANXA1-/- mice fed with 
HFD and treated with hrANXA1 (rescue experiment) had no changes in the 
phosphorylation of eNOS on Ser1177 (Figure 6), indicating that hrANXA1 prevents the 
decline in eNOS phosphorylation seen in ANXA1-/- mice fed with HFD. 
 
Having shown that endogenous ANXA1 limits, and that administration of hrANXA1 
attenuates the development of peripheral insulin resistance as well as liver injury and 
kidney dysfunction caused by a HFD, we further explored the potential mechanism(s) 
underlying the observed beneficial effects of ANXA1. Activation of RhoA plays a key 
role in the development of both peripheral insulin resistance and in the development of 
microvascular complications of diabetes(17). We have previously demonstrated that 
ANXA1 interacts with RhoA(7).  Here we demonstrate that the tissue levels of ANXA1 
are decreased in mice fed a HFD (Figure 2B). This resulted in reduced phosphorylation 
of RhoA on Ser188 (increased GTPase activity) and in an increase in the phosphorylation 
of downstream effector MYPT1 on Thr853 in the kidney (Figure 7A/D), liver (Figure 
6B/E) and skeletal muscle (Figure 7C/F), when compared to chow-fed WT-mice.  
Interestingly, ANXA1-/- mice also have a reduced phosphorylation of RhoA on Ser188 
(Figure 7A-C), and an increased phosphorylation of MYPT1 on Thr853 (Figure 7D-F) 
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(regardless of dietary manipulation) in kidney and skeletal muscle, suggesting that 
ANXA1-/- mice have constitutively activated RhoA-GTPase. Treatment of ANXA1-/- 
mice fed a HFD with hrANXA1 (rescue experiment) resulted in an increase in the 
degree of phosphorylation of RhoA on Ser188 (Figure 7A-C) and attenuation of the 
degree of phosphorylation on MYTP1 on Thr853 (Figure 7D-F), in liver, kidney and 
skeletal muscle; demonstrating conclusively that ANXA1 regulates RhoA activity. 
 
From a therapeutic point of view, treatment of WT HFD-fed mice with hrANXA1, also 
restored the tissue levels of ANXA1 in liver, kidney and skeletal muscle (Figure 2B). 
This prevented the reduction of the phosphorylation of RhoA on Ser188 (Figure 7A-C), 
and the associated increase in phosphorylation of MYPT1 on Thr853 (Figure 7D-F) 
observed in HFD-fed WT-mice. These findings support the view that ANXA1 regulates 
the activity of RhoA in experimental diabetes, which, in turn, limits the development 
of peripheral insulin resistance and protects the kidney and liver from functional 
decline. 
 
6. ANXA1 protects against excessive proton leak via FPR2 in human hepatocytes. 
One of the major sites of both lipid and glucose handling is the liver. Therefore, we 
wanted to investigate whether ANXA1 is involved in the regulation of energy 
homeostasis in human hepatocytes. Therefore, in order to evaluate whether hepatic 
mitochondrial respiration was altered under high glucose conditions, oxygen 
consumption rate (OCR) was measured (Figure 8A). HEPG2 cells grown in high 
glucose medium had higher basal OCR (Figure 8B), increased ATP-linked OCR 
(Figure 8C) leading to excessive proton leak (Figure 8D), which can lead to the 
formation of reactive oxygen species and cellular damage.  When HEPG2 cells were 
incubated in high glucose (25 mM) medium in the presence of hrANXA1, hrANXA1 
attenuated the increases in basal OCR (Figure 8B), ATP-linked OCR (Figure 8C), and 
proton leakage (Figure 7D). We hypothesized that the observed beneficial effects of 
treatment with hrANXA1 are mediated though the FPR2 receptor. Interestingly, 
expression levels of FPR2 was not altered by exposure of HEPG2 cells to high glucose 
(25 mM) medium, whereas ANXA1 levels were decreased (figure 8E). Using a specific 
FPR2 antagonist, we were able to block the effects of hrANXA1 on basal OCR (Figure 
8B), ATP-linked OCR (Figure 8C) and proton leak (Figure 8D) suggesting the 
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beneficial effects of hrANXA1 in reducing excessive proton leak are, indeed, FPR2 
mediated.  
 
7. Effects of hrANXA1 on MAPK and Akt pathway are FPR2 mediated in human 
hepatocytes 
To get a better understanding of the signaling pathways modulated by hrANXA1 in 
HepG2 cells during exposure to high glucose, the phosphorylation states of 43 
potentially relevant pathways were measured using a human phospho-kinase proteome 
profiler array (Figure 8F and Supplemental figure 1). Our results demonstrate that 
HepG2 cells grown in high glucose medium (25 mm) had an increase in 
phosphorylation of key members of the MAPK pathway (p38, JNK, ERk1/2 and 
RSK1/2) and in the Akt pathway (Akt, GSK-3B, p70 and PRAS40), while key members 
of the pro-inflammatory JAK/STAT pathway exhibited decreased inhibitory 
phosphorylation (Stat2 and Stat5a). When HepG2 cells were grown in high glucose 
medium and treated with hrANXA1, the observed increases seen in the phosphorylation 
of the MAPK (p38, JNK, ERk1/2 and RSK1/2) and the Akt pathway (GSK-3B, p70 
and PRAS40) were attenuated. Additionally, AMPKa2 phosphorylation was further 
increased in the presence of hrANXA1. Pre-incubation with an FPR2 antagonist 
abolished all of the above effects of treatment with hrANXA1, strongly suggested that 
ANXA1 is signaling through FRP2 (Figure 8F).  
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Discussion 
The key findings of our study are that patients with T2D have elevated plasma ANXA1 
levels, which correlate positively with fatty liver index and serum lipid levels, but not 
with markers of systemic inflammation, suggesting that the ANXA1 levels in patients 
with T2D are not regulated by systemic inflammation, but are a consequence of aberrant 
lipid handling. To elucidate the role of ANXA1 in the pathophysiology of 
obesity/metabolic syndrome, we used a model of HFD-induced insulin resistance in 
WT and ANXA1-/- mice. Consistent with our patient data, mice fed a HFD showed 
elevated serum ANXA1 levels, while their tissue levels were reduced (see below). 
ANXA1-/- mice fed a HFD developed a more severe diabetic phenotype (compared to 
WT mice) as indicated by higher fasting glucose levels, increased impairment in the 
oral glucose tolerance test and increased impairment of insulin signaling (IRS-1, Akt 
and GSK-3). Additionally, treatment of WT-mice fed a HFD with hrANXA1 reduced 
the diabetic phenotype, restored IRS-1 and Akt (liver and skeletal muscle) and eNOS 
(kidney) activity. ANXA1-/- mice fed on a HFD also developed severe dyslipidemia, 
hepatosteatosis (lipid accumulation in the liver) and renal dysfunction (proteinuria), 
while the therapeutic administration of hrANXA1 attenuated both hepatosteatosis and 
the renal dysfunction/proteinuria caused by HFD. HFD-fed mice had lower intracellular 
levels of ANXA1 in the kidney, liver and skeletal muscle resulting in the activation of 
small GTPase RhoA and of the downstream effector MYTP1: This key finding was 
confirmed in ANXA1-/- mice, which had constitutively activative RhoA. Treatment 
with hrANXA1 restored intracellular ANXA1 levels, reduced RhoA activation and 
restored IRS-1 signaling. Thus, we demonstrate here for the first time a mechanistic 
link between ANXA1 levels, RhoA activity and IRS-1 signaling.  Treatment of human 
hepatocytes with hrANXA1 also reduced the mitochondrial proton leak in an FPR2-
dependent manner. All of the above findings support the conclusions that endogenous 
ANXA1 prevents the development of insulin-resistance and associated microvascular 
complications, while pharmacologically administered hrANXA1 attenuates the 
development of metabolic and secondary microvascular complications in experimental 
T2D. 
 
What, then, is the mechanism(s) by which ANXA1 attenuates insulin resistance in 
experimental T2D and protects against the development of secondary complications? 
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The observed impairment in glucose tolerance seen in mice fed on a HFD is, in part, 
mediated by alterations in insulin signaling in liver and skeletal muscle. The IRS-
1/Akt/GSK-3β signaling cascade is a key regulator of glucose transportation, glycogen 
synthesis and energy metabolism (glycolysis)(18). Peripheral insulin resistance is 
attributed to an increase in the phosphorylation of Ser307 on IRS-1; this uncouples IRS-
1 from the insulin receptor blunting the ability of insulin to signal through its receptor, 
which, in turn, reduces GLUT4 translocation to the cell surface to facilitate glucose 
uptake in peripheral organs, leading to hyperglycemia (19). Mice fed a HFD showed 
increased phosphorylation of Ser307 on IRS-1 (in the liver/skeletal muscle), which was 
further augmented in ANXA1-/- mice. In contrast, treatment with hrANXA1 attenuates 
this increase in the phosphorylation of Ser307 on IRS-1 resulting 
restoration/maintenance of normal glucose levels in the blood (20).  
 
Many of the beneficial effects of anti-diabetic drugs are mediated through inhibition of 
the GTPase RhoA. Metformin reduces RhoA activity and activates AMPK (21), (22), 
while Fasudil, a selective RhoA inhibitor used to treat diabetic nephropathy, improves 
insulin signaling and nephropathy by correcting glucose and lipid homeostasis in obese 
Zucker rats (23),(24),(25). Statins, which are best known for their lipid-lowering 
effects, also ameliorate the progression of diabetic nephropathy, and both effects have 
been attributed to inhibition of RhoA/ROCK (26),(27),(28),(29),(30). Interestingly, 
RhoA activation is inhibited by ANXA1 (7), suggesting an original mechanistic link 
between ANXA1 levels, RhoA activation and the development of insulin resistance. 
We demonstrate that mice fed a high fat diet have an increase in the circulating levels 
of ANXA1, but this was associated with reduced expression in skeletal muscle, liver, 
kidney, which (in turn) resulted in activation of RhoA. However, we do not know 
whether the circulating ANXA1 measured in animals and man is inactive or whether 
the subsequent treatment restores the loss of the biological activity; though we need to 
take in consideration the limited comparability of the mouse model vs the human 
condition. Moreover we also demonstrate that ANXA1-/- mice have constitutively 
activated RhoA activity suggesting that ANXA1 is a regulator of RhoA activity. Thus, 
we propose that endogenous ANXA1 is a regulator of RhoA/ROCK activity under 
physiological conditions. Indeed, treatment of HFD-fed mice with hrANXA1 restored 
intracellular ANXA1 levels/signaling (Figure 2B), modulated RhoA phosphorylation 
and re-stabilized the insulin receptor (resulting in reduced phosphorylation of IRS-1) 
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allowing restoration of insulin signaling and glucose homeostasis. Cristante et al. (7) 
have previously demonstrated in the brain microvascular endothelium that ANXA1 and 
RhoA co-precipitate together suggesting a direct molecular interaction. Here we 
demonstrate for first time a mechanistic link between ANXA1, RhoA and IRS-1 
signaling in vivo. 
 
Impairments in insulin sensitivity are associated with excessive lipid deposition (19). 
WT mice fed on a HFD developed dyslipidemia, had excessive fat accumulation in 
their peripheral fat beds (Table 1) and in the liver causing hepatic steatosis and liver 
injury (elevated ALT levels), all of which were more severe in ANXA1-/- mice. In 
contrast, mice fed a HFD and treated with hrANXA1 show reduced adiposity, and a 
reduction in lipid and triglyceride accumulation in the liver. Collectively, our findings 
suggest that ANXA1 reduces the development of hepatic steatosis and the associated 
liver injury by inhibition of RhoA activity and restoration of IRS-1 signaling. Indeed, 
our human data shed further light on the role of ANXA1 in lipid homeostasis, as 
ANXA1 plasma levels correlate positively with increased lipids in both the liver and 
the circulation, but do not correlate with systemic inflammation, suggesting a new 
biological function of ANXA1 beyond those of as an anti-inflammatory mediator.  
 
We also report here that mice fed a HFD have reduced phosphorylation (Ser473) and, 
hence, reduced activation of Akt. Activated Akt regulates inflammatory and pro-
survival responses (31). We also show in human hepatocytes that treatment with 
ANXA1 re-activated Akt in an FPR2-dependent manner. One consequence of 
inhibition of Akt is that organs are less resistant to stressor stimuli including 
hyperglycemia and/or hyperlipidemia and subsequently develop organ injury (15). In 
contrast, restoration of the degree of activation of the Akt pathway reduces organ injury 
in many conditions associated with inflammation including sepsis-induced organ 
dysfunction (32),(33), hemorrhagic shock-induced organ dysfunction (34),(35), and 
diabetes (6)(19). The N-terminal peptide of ANXA1 (Ac2-16) also reduces tissue injury 
by activating Akt in experimental models of cardiac/renal reperfusion injury(36),(37) 
and non-alcoholic steatohepatitis (38). Activation of Akt also results in inhibition GSK-
3β (Ser9 phosphorylation) resulting in activation of glycogen synthase, which converts 
glucose to glycogen for storage in the liver. Here we demonstrate that mice fed on a 
HFD have decreased activation of GSK-3β, which could result in a reduction in 
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glycogen synthesis and increased blood glucose levels. In contrast, mice treated with 
hrANXA1 have restored phosphorylation of GSK-3β; allowing for the enzymatic 
conversion of glucose to glycogen.  
 
We demonstrate using extracellular flux assay that hyperglycemia alter mitochondrial 
function resulting in the production of excessive protons, that can lead to the production 
of excessive ROS, which primarily damage the mitochondria. Here we shown that 
hrANXA1 protects the mitochondria from the detrimental effects of hyperglycemia in 
an FPR2-dependent manner. Consistent with previous in vivo data (6) we show that the 
treatment of human hepatocytes grown in under high glucose with hrANXA1attenuates 
the activation of MAPK  and restores Akt and GSK-3β activity. Incubation of HEPG2 
cells with normal (5.5 mM) results in co-localization of ANXA1 and FPR2 on the 
plasma membrane. In contrast, treatment of these cells with high glucose (25mM) 
results in a clear separation of the localization of ANXA1 and FPR2  (Figure 9). Such 
data further clearly suggests that high glucose conditions effects ANXA1 distribution 
and its inability to work in an autocrine way (39).  
 
Insulin resistance results in the development of microvascular complications including 
diabetic nephropathy. ANXA1-/- mice fed a HFD have more severe renal dysfunction 
(proteinuria and a reduction in GFR) when compared to WT mice fed on a HFD diet.  
Patients with T2D display endothelial dysfunction, which is associated with an 
increased cardiovascular risk (40). Several lines of evidence suggest that decreased 
endothelial nitric oxide synthase (eNOS) phosphorylation is a molecular mechanism 
linking aberrant metabolism and vascular dysfunction: (i) eNOS phosphorylation is 
diminished in diabetes, hypercholesterolemia, and atherosclerosis (41),(42),(43), (ii) 
anti-diabetic drugs including statins and PPAR agonists increase eNOS 
phosphorylation (38), and (iii) signaling molecules including insulin, IGF-1 and leptin 
increase eNOS phosphorylation (40).  Here we demonstrate that mice fed on a HFD 
have decreased eNOS phosphorylation (in the kidney), which was restored by 
hrANXA1 treatment. The present study shows that mice fed a HFD have decreased Akt 
and eNOS activity, while both of these signaling events are attenuated by treatment 
with hrANXA1. Indeed, inhibition of RhoA/ROCK by statins or other selective 
inhibitors leads to the up regulation and activation of eNOS (44), potentially through 
restoration of Akt signaling (40). We also demonstrate that inhibition of RhoA 
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attenuates the activity of MYTP1. MYPT1 is a key regulator of vascular tone within 
vascular smooth muscle. Activated (phosphorylated) MYPT1 actively phosphorylates 
myosin delaying its ability to relax, therefore, inducing prolonged contraction (45),(46) 
suggesting there could be a link between ANXA1 and the development of hypertension 
(however this warrants further investigation). 
 
We report here for the first time that plasma levels of AXNA1 are also elevated in 
patients with T2D, thus supporting the hypothesis that increased circulating ANXA1 
levels are indicative of an immune-metabolic state. Obesity is one of the strongest 
etiological predictors for developing T2D and of adverse cardiovascular outcomes. 
Here we clearly demonstrate a positive correlation between increased hepatic steatosis 
(fatty liver index), waist circumference (Table 1) and elevated plasma ANXA1 levels 
(Figure 1A); suggesting that high ANXA1 levels may also be a biomarker of the 
development of fatty liver disease (although this hypothesis warrants further 
investigation). Dyslipidemia is a key predictive factor for both the development of T2D 
and adverse cardiovascular events. Here we show for the first time a strong positive 
correlation between elevated total cholesterol and LDL-C and elevated plasma ANXA1 
levels. Critically, ANXA1 levels were not correlated with CRP and marker of chronic 
inflammation. This is consistent with our previous finding showing that ANXA1 levels 
did not correlate with CRP in patients with type-1 diabetes. We hypothesize that 
ANXA1 is released from cellular stores into the circulation in response to an aberrant 
physiological conditions (6) where it is known to signal in both an autocrine and 
paracrine manner through Formyl-Peptide receptors to elicit both anti-inflammatory 
and tissue protective effects (5). Two independent lines of evidence support this 1) 
ANXA1 levels are elevated in both patients and mice with T2D and 2) tissue levels of 
ANXA1 are decreased in HFD-fed mice (Figure 1) suggesting it has been released from 
intracellular stores. 
 
Conclusions  
In conclusion, we report here for the first time that mice fed a HFD develop insulin 
resistance, while endogenous ANXA1 dampens the development of both the diabetic 
phenotype and the associated hepatic steatosis and nephropathy (proteinuria). Most 
notably, treatment with hrANXA1 re-establishes normal insulin signaling and 
attenuates the development of hepatosteatosis and diabetic nephropathy. ANXA1 
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regulates and inhibits RhoA activity in vivo. In murine diabetic tissues, expression of 
ANXA1 is decreased allowing for the activation of RhoA, while treatment with 
hrANXA1 inhibits RhoA activity, decreases insulin resistance and restores Akt and 
eNOS signaling. Finally, we demonstrate that patients with T2D have elevated plasma 
levels of ANXA1. Thus, we propose that elevated levels of ANXA1 may represent a 
novel biomarker for the development of hepatosteatosis and that hrANXA1 or its 
peptide mimetics may be useful in the treatment of T2D and/or its complications. 
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Table 1: Detail of patients included in the study 
Number of patients per group, age, gender, fasting glucose, Hb1Ac, BMI, waist 
circumference serum, cholesterol, HDL, LDL-C, triglyceride, C-reactive protein 
(CRP), ALT, AST, GGT, FLI, creatinine, GFR and urinary albumin. Experimental 
groups: Normoglycemic (n=30) and patients with type-2 diabetes (T2D, (n=65). Data 
analyzed by unpaired Student’s t-test (normally distributed data) or Mann Whitney U 
test (data that are not normally distributed) and expressed as mean ± SEM. * = p<0.05; 
NA= data not available. 
 
 
 
 Normoglycemic T2D 
Number 
(n) 
30 65 
Age (years) 71 ± 0.4 69 ± 0.9 
Gender  
(F %) 
13 (43) 46 (35) 
Fasting glucose  
(mg/dL) 
101.3 ± 1.2 171.7 ± 5.6* 
Hb1Ac (%) N/A 7.37 ± 0.1 
BMI  
(kg/m2) 
26.3 ± 0.6 31.4 ± 0.8* 
Waist Circumference 91.3 ± 1.5 105.91 ± 1.74* 
Total cholesterol  
(mg/dL) 
189.5 ± 4.8 187.27 ± 5.48 
HDL-C 
 (mg/dL) 
59.7 ± 1.7 48.02 ± 1.85* 
LDL-C  
(mg/dL, Friedewald) 
109.7 ± 4.3 109.61 ± 4.70 
Triglycerides  
(mg/dL) 
100.1 ± 5.3 148.26 ± 17.4* 
C-Reactive Protein  
(mg/dL) 
0.12 ± 0.02 0.58 ± 0.2* 
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Alanine Aminotransfersae (ALT)  
(U/L) 
19.54 ± 0.96 31.89 ± 4.8* 
Aspartate Aminotransferase (AST) 
(U/L) 
24.08 ± 0.61 26.71 ± 3.1* 
Gamma Glutamyl Transpeptidase 
(GGT) 
(U/L) 
28.6 ± 3.15 35.16 ± 2.7* 
Fatty Liver Index (%) 37.1 ± 5.7 66.14 ± 3.31* 
Creatinine  
(mg/dL) 
0.9 ± 0.04 1.8 ± 0.1* 
GFR  
(mL/min) 
71.3 ± 2.34 29.7 ± 1.8* 
Urinary albumin  
(mg/g urinary protein) 
N/A 202.0 ± 48.1 
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Table 2: Animals biochemistry 
 
Body weight gain from baseline, epididymal fat weight, inguinal fat weight, blood 
glucose, serum insulin and OGTT AUC were measured in WT C57BL/6 or ANXA1-
/- mice fed a standard diet (chow) or a high-fat diet (HFD) for 10 weeks. HFD-mice 
were treated with either vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) 
five times per weeks between weeks 4 and 10. Data are expressed as mean± SEM of 7-
10 mice per group. Data were analyzed by a one-way ANOVA followed by a 
Bonferroni post-hoc test, *p< 0.05vs. WT + HFD or $p<0.05 vs, ANXA1 + HFD. 
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    Wild Type     ANXA1 -/-   
  
Chow 
Chow + 
hrANXA1 
HFD+ Vehicle 
HFD + 
hrANXA1 
Chow 
HFD + 
Vehicle 
HFD + 
hrANXA1 
Body weight (g) 9.790±0.602* 9.857±0.674* 16.81±0.479 12.87±0.455* 4.550±0.276$ 13.89±0.772 7.00±0.447$ 
Epididymal fat 
(mg) 1.963±0.163* 2.100±0.255* 3.570±0.291 2.867±0.253* 2.288±0.067$ 5.609±0.246 4.361±0.007$ 
Inguinal fat (mg) 1.250±0.128* 1.275±0.149* 2.320±0.243 1.833±0.212* 0.714±0.051$ 1.842±0.096 1.370±0.094$ 
Blood glucose 
(mmol/L 8.438±0.541* 7.682±0.29* 13.86±0.6621 9.088±0.442* 8.650±0.493$ 19.56±1.224 8.483±0.541$ 
Serum Insulin 
(ng/mL) 6.6941.282* 7.110±1.061* 18.73±2.454 7.860±0.697* 5.321±0.238$ 20.54±1.271 13.47±0.817$ 
OGTT (AUC) 84.42±4.506* 84.96±3.659* 110.7±3.659 89.42±0.999* 87.65±4.716$ 127.6±3.767 99.93±3.560$ 
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Legend to figures 
Figure 1.  Assessment of ANXA1 levels in patients with type-2 diabetes.  
(A) Plasma ANXA1 levels measured by ELISA in age and sex match normoglycemic 
(n=30) and patients with type-2 diabetes (n=65). (B) Correlation in diabetic patients of 
plasma ANXA1 levels and: Fatty Liver (B), LDL-C (C), and total cholesterol (D). Data 
is expressed as mean± SEM., ****p< 0.0001. (B-D) 95 % confidence intervals are 
displayed of the microvascular 
 and significance estimated using Fishers F test p<0.05 was deemed significant. 
 
Figure 2. Correlation data of clinical markers in patients with type-2 diabetes and 
ANXA1. 
(A) Correlation of plasma CRP with BMI in diabetic patients. (B) Correlation of plasma 
ANXA1 levels with BMI in diabetic patients. (C) Correlation of plasma ANXA1 levels 
with CRP in diabetic patients. (D) Correlation of CRP with cholesterol in diabetic 
patients. (E) Correlation of CRP with LDL in diabetic patients. (F) Plasma ANXA1 
levels in patients with diabetes ± CKD. (A-E) display 95 % confidence intervals are 
displayed of the linear regression and significance estimated using Fishers F test p<0.05 
was deemed significant. 
 
Figure 3. ANXA1 attenuates the development of obesity and insulin resistance in 
HFD fed mice. 
C57BL/6 or ANXA1-/- mice, fed a standard diet (chow) or a high-fat diet (HFD) for 10 
weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40  µg/kg, i.p.) 
five times per week between weeks 5 and 10. A) ELISA for ANXA1 levels were 
measured in serum isolated from whole blood at harvest, (n=6) B) Western blot analysis 
of kidney, liver and skeletal muscle show a depletion in ANXA1 which was restored 
by hrANXA1 treatment (n=6/group). C) Serum insulin levels were measured in plasma 
isolated from whole blood at harvest (n=6-10/group). D) Basal non-fasted blood 
glucose was measured at week 10 one hour prior to harvest via the tail vain (n=6-
10/group). E) Oral glucose tolerance was assessed over 120 min 1 week prior to harvest 
in WT mice. F) Oral glucose tolerance was assessed over 120 min 1 week prior to 
harvest in ANXA1-/- mice. G) The area under curve (AUC) of OGTT was calculated 
for respective groups and used for statistical analysis.  
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Data analyses by a one-way ANOVA followed by a Bonferroni post-hoc test and the 
mean is expressed mean± SEM., **p< 0.01, ***p< 0.001, ****p< 0.0001; $<0.05 vs. 
WT + HFD; $$$p<0.001 $$$$p<0.0001 vs. ANXA1-/- + HFD. 
 
Figure 4. ANXA1 attenuates HFD induced development of peripheral insulin 
resistance. 
C57BL/6 or ANXA1-/- mice, fed a standard diet (chow) or a high-fat diet (HFD) for 10 
weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) 
five times per week between weeks 5 and 10. Western blot analysis for Phosphorylation 
of Ser307 on IRS-1 in Skeletal muscle (A) or liver (D) and normalized to total IRS-1; 
for phosphorylation of Ser473 on Akt in the skeletal muscle (B) and liver (E) and 
normalized to total Akt; for phosphorylation of Ser9 on GSK-3β in the skeletal muscle 
(C) and in the liver (F) and normalized to total GSK-3β. Data were analyzed by a one-
way ANOVA followed by a Bonferroni post-hoc test and the mean is expressed mean 
± SEM., *p< 0.05, ****p< 0.0001 vs. WT + HFD; $<0.05 $$$p<0.001 $$$$p<0.0001 vs. 
ANXA1-/- +HFD. 
 
Figure 5. ANXA1 attenuates induced lipid accumulation, hepatic injury and renal 
dysfunction. 
C57BL/6 or ANXA1-/- mice, fed a standard diet (chow) or a high-fat diet (HFD) for 10 
weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) 
five times per week between weeks 5 and 10. Measure of A) Serum triglyceride, B) 
Serum cholesterol, C) Liver triglyceride, D) Serum aminotransferase (ALT), n=6-
8/group. E) 18 h urine samples was collected and renal dysfunction was measured by 
albumin to creatinine ratio (ACR), n=6-8 per group. F) Creatinine clearance was 
measured from urinary and serum creatinine, n=6-8 per group. Panel G): representative 
images of hepatic lipid deposition assessed by Oil Red-O staining. Panel H: 
representative images of histological changes in kidney structure assessed by periodic 
acid-Schiff staining, yellow arrows indicating brush borders of proximal tubules.  
Data were analyzed by a one-way ANOVA followed by a Bonferroni post-hoc test and 
the mean is expressed mean ± SEM., *p<0.05, **p< 0.01, ***p<0.001, ****p< 0.0001 
vs. WT + HFD. $p<0.05, $$p<0.01 $$$p<0.001 vs. ANXA1-/- + HFD. 
 
Figure 6. ANXA1 attenuates HFD induction of eNOS in the diabetic kidney 
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C57BL/6 or ANXA1-/- mice, fed a standard diet (chow) or a high-fat high-sugar diet 
(HFD) for 10 weeks, were treated with vehicle or hrANXA1 (40 µg/kg, i.p.) five times 
per weeks between weeks 5 and 10. At harvest kidney, liver and skeletal muscle was 
harvested. Phosphorylation of eNOS was determined by western blot; a representative 
blot is shown and densitometry quantification of n=3 independent experiments. 
 
Figure 7. ANXA1 attenuates RhoA induction in mice fed a HFD. 
C57BL/6 or ANXA1-/- mice, fed a standard diet (chow) or a high-fat high-sugar diet 
(HFD) for 10 weeks, were treated with vehicle or hrANXA1 (40 µg/kg, i.p.) five times 
per weeks between weeks 5 and 10. At harvest kidney, liver and skeletal muscle was 
collected. (A-C) Phosphorylation of Ser188 on RhoA was normalized to total RhoA in 
kidney (A), liver (B) and skeletal muscle (C). (D-F) Phosphorylation of Thr853 on 
MYPT1 was normalized to total MYPT1 in kidney (D), liver (E) and skeletal muscle 
(F). A representative blot is shown for each protein and densitometry quantification of 
n=3 experiments represented in the histograms. Data were analyzed by a one-way 
ANOVA followed by a Bonferroni post-hoc test and the mean is expressed mean ± 
SEM., *p< 0.05, **p< 0.01, ***p<0.001, ****p< 0.0001 vs WT + HFD; $p<0.05, 
$$$p<0.001, $$$$p<0.0001 vs. ANXA1-/- +HFD. 
 
Figure 8: ANXA1 protects human hepatocytes from excess proton leak via FPR2. 
HepG2 cells were grown for 48 hours in 5.5 mM glucose, 25 mM glucose, 25 mM 
glucose + hrANXA1 or 25 mM glucose + hrANXA1 + WRW4. (A) Oxygen 
consumption rate was assessed using SeaHorse analyzer. (B) Basal OCR, and (C) ATP-
linked OCR and (D) proton leak. (E) Expression and localization of FPR2 and ANXA1 
assessed by immunofluorescent staining and visualized using image stream. (F) 1x106 
HepG2 cells were grown in 6 well plates and protein isolated to assess phosphorylation 
state of 43 proteins using human phospho-proteome profiler. (B-D) Data were analyzed 
by a one-way ANOVA followed by a Bonferroni post-hoc test and the mean is 
expressed mean ± SEM., **p< 0.01, ****p< 0.0001 vs HepG2 + 25 mM glucose. (F) 
Data expressed as fold change to HepG2 + 5.5 mM glucose of pooled samples from 3 
independent experiments.  
 
